Neurofibromatosis Educational Meeting

Virtual Zoom Meeting
Wednesday, April 15, 2026
7 pm CT

Join us for an engaging and informative webinar that explores how groundbreaking research and clinical trials are transforming the future of care for individuals with Neurofibromatosis Type 1 (NF1).

Dr. Colleen Niswender of Vanderbilt University and the Warren Center for Neuroscience Drug Discovery will present current NF1 research from her lab, outlining the drug discovery process—from compound identification and screening to clinical development—and how these efforts are advancing a broader treatment pipeline. Her work includes collaborations with Neumora Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, the William K. Warren Foundation, and the National Institutes of Health, with six programs reaching clinical trials. She is also leading efforts to develop new treatments for Rett syndrome, Pitt-Hopkins syndrome, and NF1.

The webinar will also feature Dr. Paul Moots, President of the Board of NF Tennessee and Board Member of the NF Network. A neurologist and neuro-oncologist, and former Director of the Neurofibromatosis Clinic at Vanderbilt University Medical Center, Dr. Moots will discuss current research trends and strategies to reduce barriers to clinical trial participation. Over his 34-year career, he has served as an investigator on 38 clinical trials focused on gliomas and other nervous system tumors, including MEK inhibitor trials for plexiform neurofibromas.

To wrap up the session, Mike Sager, Patient Education Manager at Alexion, will deliver a valuable talk on "Productive Conversations with Healthcare Providers," equipping you with essential tools for effective communication in your healthcare journey. 

Don’t miss this unique opportunity to learn how cutting-edge research is driving progress and how you can be an integral part of this transformative movement!

The event is free, but RSVP is required.

Thank you to our sponsor